9th - 10th September, Cambridge, UK
More informationJoin the community - networking, discussion and more. Open to all.
More informationCould you write an interesting article for the RQA community?
More informationThe regulation reinforcing EMA’s role in crisis preparedness and management of medicinal products and medical devices becomes applicable as of 1st March 2022. It puts some of the structures and processes established by EMA during the COVID-19 pandemic on a more permanent footing, while entrusting several new tasks to the Agency.
Human and Veterinary Highlights from 2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022
EMA’s PRIority Medicines (PRIME) scheme has had a positive impact on the authorisation of new medicines.
New bill seeks to revamp FDA’s accelerated approvals programme
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 15-16 February 2022
MHRA Good Practice Symposia Week (7 to 11 March 2022)
Blog Post - Regulators’ experience of clinical trials during the Covid-19 pandemic (Part 3) – looking forward
The next MHRA Board Meeting held in public will be conducted virtually by webinar on Tuesday, 15 March 2022 from 10.00 until 12.30 hrs. (GMT).
There are currently 5 separate events planned for March 2022.